. 2008 Apr 18;111(12):5524–5529. doi: 10.1182/blood-2007-08-109611

Table 2.

Crude odds ratios (ORs) and 95% confidence intervals (CIs) for the association between Borrelia infection and risk of non-Hodgkin lymphoma (NHL) overall and NHL subtype

	All NHLs		DLBCL		CLL		FL		MCL		MZL		LPL		TCL
	No.	OR^* (95% CI)	No.	OR^* (95% CI)	No.	OR^* (95% CI)	No.	OR^* (95% CI)	No.	OR^* (95% CI)	No.	OR^* (95% CI)	No.	OR^* (95% CI)	No.	OR^* (95% CI)
Tick bite,^† self-reported
Ever^‡	1248	1.0 (0.9-1.1)	319	0.99 (0.8-1.2)	318	1.1 (0.9-1.3)	224	0.9 (0.8-1.1)	65	1.0 (0.7-1.5)	46	1.01 (0.7-1.5)	51	1.2 (0.8-1.8)	71	0.8 (0.6-1.1)
P_homogeneity		0.90		0.92		0.49		0.35		0.83		0.95		0.42		0.17
Borrelia infection,^† self-reported
Ever^§	102	1.3 (0.96-1.8)	26	1.3 (0.8-2.1)	23	1.2 (0.8-2.0)	19	1.3 (0.8-2.2)	9	2.5 (1.2-5.1)	0	–	5	1.8 (0.7-4.7)	8	1.8 (0.8-3.8)
P_homogeneity		0.09		0.24		0.40		0.35		0.03		–		0.26		0.16
*Anti-Borrelia* antibodies^‖**
Positive^¶	73	1.3 (0.9-2.0)	18	1.4 (0.8-2.5)	23	1.0 (0.6-1.8)	13	1.1 (0.6-2.1)	12	3.6 (1.8-7.4)	2	1.1 (0.3-4.6)	0	–	3	0.7 (0.2-2.5)
P_homogeneity		0.15		0.24		0.87		0.79		0.001		0.94		–		0.61

NHL indicates non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; LPL, lymphoplasmacytic lymphoma; and TCL, T-cell lymphoma.

Adjusted for sex, age in 10-year intervals, and country of residence (matching variables).

^†

Including answers of all SCALE participants (3055 NHL cases and 3187 matched controls).

^‡

Reference: never have had a tick bite.

^§

Reference: never have had an injection with B burgdorferi.

^‖

Borrelia-specific IgG antibodies were analyzed in a case-control study subset including serum samples of 1579 cases with NHL and 1358 matched controls; in 6 participants (2 cases and 4 controls), serologic analyses yielded inconclusive results and were excluded.

^¶

Reference: negative for Borrelia-specific IgG antibodies in serum.